Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study Meeting Abstract
| Authors: | Foran, J. M.; DiNardo, C. D.; Watts, J. M.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A.; Stone, R. M.; Patel, P. A.; Tallman, M. S.; Choe, S.; Wang, H.; Zhang, V.; Fan, B.; Yen, K. E.; Oluyadi, A.; Winkler, T.; Hickman, D.; Agresta, S. V.; Liu, H.; Wu, B.; Attar, E. C.; Kantarjian, H. M. |
| Abstract Title: | Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164602277 |
| DOI: | 10.1182/blood-2019-123946 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4254 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work